#kidney disease

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

The short treatment could make transplantation of organs from donors with HCV more safe, effective and economical.

While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.

With every centimeter increase in waist circumference, the risk of severe fibrosis rose by 5%.

A growing number of transplant programs are barring patients who refuse COVID vaccines or giving them lower priority on waiting lists.

Among people treated for hepatitis C, diabetes and chronic kidney disease were both linked to a higher risk of cardiovascular death.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Hepatitis C affects more than just the liver. Hep C can have serious health impacts long before there are signs of advanced liver disease.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

March is National Kidney Month, and an opportune time to look at hepatitis C and the kidneys.

A pooled analysis of numerous studies found the safety and efficacy of the regimen was comparable between those under and those over 65.

The hepatitis C regimen was tested in a small group with severe kidney impairment.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

An analysis of forty-two clinical trials of all the approved direct acting antiviral HCV regimens.